Clinical trials
Esophageal Squamous Cell Cancer clinical trials
Below are recruiting esophageal squamous cell cancer clinical trials, each written for real people, not researchers. We’re tracking 261 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07622797RecruitingPhase 2
Immunotherapy with chemotherapy and radiation for esophageal cancer
This trial tests a new immunotherapy drug (camrelizumab) combined with standard chemotherapy and radiation to treat advanced esophageal cancer while avoiding surgery if possible. The goal is to shrink the tumor and help you keep your esophagus working.
Luoyang, HenanAges 18 years+ - NCT05894369Recruiting
Testing how the tumor environment affects pre-op chemo plus immunotherapy
This study looks at people with esophageal squamous cell carcinoma to see how changes in the “tumor neighborhood” may affect how well treatment works before surgery. If you’re eligible, you would receive chemotherapy plus immunotherapy as neoadjuvant (before-surgery) treatment.
Wuhan, HubeiAges 18–80 - NCT06709417RecruitingPhase 2
Immunotherapy plus chemo and radiation for advanced esophageal cancer
This trial is testing whether giving a combination of an immunotherapy drug (sintilimab) with chemotherapy, followed by radiation plus more chemotherapy (concurrent chemoradiotherapy), can help people with advanced esophageal cancer that cannot be removed surgically. The goal is to see if this approach shrinks the tumor and improves outcomes.
Shanghai, Shanghai MunicipalityAges 20–75 - NCT06718205RecruitingPhase 2
Nimotuzumab plus immunotherapy and chemo for esophageal cancer
This study tests a new combination of drugs for advanced esophageal cancer. It adds an antibody (nimotuzumab) and an immunotherapy (sintilimab) to standard chemotherapy, aiming to improve how well treatment works.
Zhengzhou, HenanAges 18–75 - NCT07578571RecruitingPhase 1
Testing a New Cancer Treatment Called IM-1617
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
New Haven, ConnecticutAges 18 years+ - NCT04278287RecruitingPhase 1/Phase 2
Chemoradiation study for unresectable esophageal cancer
This Phase 1/2 trial tests a treatment plan using chemotherapy plus radiation for esophageal squamous cell cancer that cannot be removed with surgery. It may help shrink or control the cancer and guide safer dosing, but it’s only for people with specific tumor stage, health status, and blood test results.
Anyang, HenanAges 18–75 - NCT07554521RecruitingPhase 2
Tislelizumab Plus Chemotherapy for Advanced Stomach or Esophageal Cancer
This study tests a combination of two drugs—tislelizumab (an immunotherapy) and chemotherapy—to treat advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be surgically removed. The trial focuses on recruiting patients from racial and ethnic minority communities to ensure the treatment is studied in diverse populations.
Cerritos, CaliforniaAges 18 years+ - NCT05214222RecruitingPhase 2
New treatment for advanced esophageal cancer after past therapy
This Phase 2 trial tests penpulimab plus chemotherapy (with or without an added targeted pill called anlotinib) in people with advanced esophageal squamous cell carcinoma. It aims to slow tumor growth and improve outcomes, especially for patients who can’t have curative surgery or radiation.
Guangzhou, GuangdongAges 18–75 - NCT07530094RecruitingPhase 2
Radiation and chemotherapy with immunotherapy for advanced esophageal cancer
This trial tests a combination of radiation, chemotherapy (cisplatin and paclitaxel), and an immunotherapy drug called camrelizumab for patients with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if adding immunotherapy improves outcomes compared to standard treatment alone.
Nanjing, JiangsuAges 18–75 - NCT06755866Recruiting
Predicting chemo-radiation response with improved MRI for esophageal cancer
This trial uses a special MRI technique to see if it can predict how well esophageal cancer responds to chemo-radiotherapy before surgery. It may help doctors choose the best treatment plan for you.
Kunming, YunnanAges 18–80 - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Denver, ColoradoAges 18 years+ - NCT07505186RecruitingPhase 2
Immunotherapy and chemotherapy before surgery for esophageal cancer
This trial tests a combination of an immunotherapy drug (camrelizumab), chemotherapy, and another targeted drug (ivarmacitinib) before surgery for esophageal cancer. The goal is to see if this treatment can shrink the tumor before it is removed, potentially improving outcomes.
Hangzhou, ChinaAges 18–75 - NCT07489066RecruitingPhase 2
Study of PF-08634404 for early-stage or locally advanced lung cancer
This trial tests a new drug, PF-08634404, alone or with other treatments, for people with early-stage or locally advanced non-small cell lung cancer (NSCLC) that can be surgically removed or has been treated with radiation and chemo. It aims to find if the drug helps before or after surgery or after standard treatments.
Huntsville, AlabamaAges 18 years+ - NCT07481058RecruitingPhase 2
Study of KC1036 with immunotherapy and chemo for advanced esophageal cancer
This trial tests a new drug called KC1036 combined with standard immunotherapy and chemotherapy for people with advanced esophageal cancer that has not been treated before. The goal is to see if this combination can help shrink tumors and improve outcomes.
BeijingAges 18–75 - NCT06489197RecruitingPhase 2
AK112 plus chemo for advanced esophageal cancer
This trial tests a new immunotherapy drug (AK112) combined with chemotherapy as a first treatment for advanced esophageal cancer that has spread or cannot be removed. It aims to see if this combination helps shrink tumors and controls the disease longer than chemotherapy alone.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07463573RecruitingPhase 3
New drug vs chemotherapy for advanced esophageal cancer
This trial tests a new drug, QLC5508, against standard chemotherapy for people with advanced esophageal cancer that has already been treated. It aims to see if the new drug works better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07455019RecruitingPhase 2
Immunotherapy, targeted therapy, radiation, and chemo for limited spread esophageal cancer
This trial tests a combination of an immunotherapy drug (bemosubaymab), a targeted therapy (anlotinib), radiation therapy, and chemotherapy for patients with esophageal cancer that has spread to a limited number of spots (no more than 5). The goal is to see if this combination can shrink or control the cancer.
Nanjing, JiangsuAges 18 years+ - NCT07437898RecruitingPhase 2
Adebrelimab plus chemo before surgery for esophageal cancer
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy, given before surgery, helps shrink esophageal cancer tumors and improves outcomes. It is for people with a specific type of esophageal cancer that has not spread widely.
Putian, FujianAges 18–75 - NCT07435454RecruitingPhase 2
Oral paclitaxel plus radiation for advanced esophageal cancer
This trial tests a combination of an oral chemotherapy drug (paclitaxel) and radiation therapy for people with advanced esophageal cancer that cannot be removed by surgery. It may be an option if you are 70 or older or cannot tolerate IV chemotherapy and have trouble swallowing.
Nanjing, JiangsuAges 70 years+ - NCT07405086RecruitingPhase 4
Morning versus afternoon immunotherapy for advanced cancer
This trial tests whether getting your immunotherapy infusion in the morning or in the afternoon makes any difference in how well it works. If you have certain types of advanced cancer and are about to start a standard FDA-approved immunotherapy, this study may help you and others by finding the best time of day for treatment.
Portland, OregonAges 18 years+ - NCT07405190RecruitingPhase 2
Ivonescimab with or without chemo for advanced NSCLC
This study tests a new drug, ivonescimab, alone or with chemotherapy (carboplatin and pemetrexed), for people with advanced lung cancer that has specific gene changes and has already been treated with targeted therapy. It aims to see if the drug can shrink tumors or slow the cancer's growth.
Boston, MassachusettsAges 18 years+ - NCT07390838RecruitingPhase 1
Study of SH009 for advanced solid tumors
This trial tests an investigational drug called SH009 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
ShanghaiAges 18 years+ - NCT07371247Enrolling by invitationEarly Phase 1
Adjuvant treatment guided by ctDNA after chemoradiation for esophageal cancer
This trial tests whether adjusting treatment based on a blood test (ctDNA) after standard chemoradiation can improve outcomes for patients with advanced esophageal squamous cell carcinoma. It aims to find a more personalized approach to prevent cancer recurrence.
Nanjing, JiangsuAges 18–80 - NCT07359417RecruitingPhase 1
MR-guided radiation boost for esophageal cancer
This trial tests whether giving a higher dose of radiation to the main tumor, guided by MRI scans, can improve treatment for a type of esophageal cancer called squamous cell carcinoma. You would first receive standard chemoradiation followed by surgery.
Utrecht, UtrechtAges 18 years+
Hear when a new Esophageal Squamous Cell Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for esophageal squamous cell cancer?
- Yes. Clin2 currently lists 261 recruiting esophageal squamous cell cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a esophageal squamous cell cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a esophageal squamous cell cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.